Clinical Trials
13 trialsNCT04752826 2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2 Recruiting
NCT07230613 2026-02-11
NEOREM-NEO-1
UNICANCER
Phase 2 Recruiting
NCT06784648 2025-11-19
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
BioInvent International AB
Phase 1/2 Active not recruiting
NCT06159842 2025-02-12
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
The Center for Clinical and Cosmetic Research
Phase 2 Completed
NCT04929535 2022-08-30
Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Unknown
NCT03322293 2022-03-09
Daylight Photodynamic Therapy for Actinic Keratosis
University of California, San Francisco
Phase 1 Completed
NCT02751151 2021-10-06
PDT
Inova Health Care Services
Phase NA Completed
NCT02157623 2020-07-30
Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome
The Cleveland Clinic
Phase NA Completed
NCT02239679 2018-08-24
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT02632110 2018-01-18
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
DUSA Pharmaceuticals, Inc.
Phase 2 Completed
NCT03024060 2017-11-07
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
DUSA Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT02137785 2015-09-16
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
DUSA Pharmaceuticals, Inc.
Phase 3 Completed
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated